BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline

About this update from Bionxt Solutions Inc

[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to announce two key milestones in the expansion and protection of its proprietary drug delivery platform targeting neurological autoimmune disorders. The Company has formally initiated the prioritized examination process for its U.S. patent application for BNT23001, a novel sublingual thin-film cladribine formulation for multiple sclerosis (MS), under the United States Patent and Trademark Office's (USPTO) Track One Program. Simultaneously, BioNxt has received acceptance of core claims for a broad international patent designed as a platform-level umbrella protecting the Company's sublingual thin-film delivery technology across a wide range of diseases, drug compounds, and applications.","length":948,"tagName":"p"},{"type":"text","content":"Fast-Tracked U.S. Patent Filing via Track One to Accelerate Clinical Development Milestones","length":91,"tagName":"p"},{"type":"text","content":"BioNxt is pursuing the USPTO's Track One Prioritized Examination Program to accelerate patent review for BNT23001. Once accepted, this program enables final patent disposition within 12 months, with most applicants receiving a first Office Action in approximately two months and a final decision in under seven months. For BioNxt, this fast-track status represents a strategic opportunity to secure near-term U.S. patent protection and strengthen its IP position ahead of pivotal bioequivalence studies and commercial partnering discussions.","length":545,"tagName":"p"},{"type":"text","content":"BNT23001 is an orally dissolvable thin-film formulation of cladribine, a well-established immunomodulatory compound. Delivered sublingually, the formulation is designed for improved bioavailability, faster onset of action, and enhanced patient compliance, particularly in populations affected by dysphagia or seeking non-invasive alternatives to traditional tablets or injections.","length":380,"tagName":"p"},{"type":"text","content":"A Strategic Path Toward Superbioavailability and Rapid Approval","length":63,"tagName":"p"},{"type":"text","content":"BioNxt is advancing BNT23001 for relapsing-remitting MS (RRMS) an...

More updates from Bionxt Solutions Inc